Physician profile
Rafael Serrano
NPI 1235589599
$35,638.96
in general payments reported to CMS, 2019-2025
9 companies · $504 in 2025
The $504 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $14K · 2023: $190 · 2024: $245 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mid-Atlantic Surgical Systems, LLC | $15,676.31 | 2021-2022 | |
| Arthrex, INC. | $10,708.61 | 2021 | |
| Smith+Nephew, INC. | $7,570.13 | 2021-2025 | Bone Anchors With Arthroscopic Delivery System, Firstpass, Q-Fix |
| Stryker Corporation | $990.48 | 2021-2025 | Gamma, Pangea, T2 |
| Moximed, INC | $236.30 | 2024-2025 | Misha Knee System, Small, Left |
| Depuy Synthes Sales INC. | $181.27 | 2023-2024 | Fibulink, Fibergraft Bg Morsels |
| Linvatec Corporation | $136.05 | 2022-2024 | Biobrace 23mm, Allograft Tissue |
| Axogen | $121.16 | 2021 | |
| Vericel Corporation | $18.65 | 2024 | Maci |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.